Nurix Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Nov 30, 2025 was Collaboration Revenue at $54.0 million, 64% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Aug 31, 2026
|
FY 2025
Nov 30, 2025
|
FY 2024
Nov 30, 2024
|
FY 2023
Nov 30, 2023
|
FY 2022
Nov 30, 2022
|
FY 2021
Nov 30, 2021
|
FY 2020
Nov 30, 2020
|
|---|---|---|---|---|---|---|---|
| Revenue |
702
|
84
|
55
|
77
|
39
|
30
|
18
|
| Collaboration Revenue |
49
-9.1%
share 6.9%
|
54
-1.0%
share 64.3%
|
55
-4.3%
share 100.0%
|
57
+47.5%
share 74.0%
|
39
share 100.0%
|
—
|
—
|
| License Revenue |
653
share 93.1%
|
30
share 35.7%
|
—
|
20
share 26.0%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRIX (Nasdaq)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1549595
- Former names
- Nurix, Inc. (until Sep 18, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.